Creo Medical has announced its interim results to 30 June 2018. Undoubtedly this has been a strong period for the company with its lead product having been used clinically outside of the UK for the first time. Additionally, framework distribution agreements have been completed in the UK and South Africa and with Pentax in Asia-Pacific and 45 clinicians have been successfully trained as of 28 August 2018. Post-period end the company successfully raised £48.5m (gross) in an oversubscribed placing. ....
28 Sep 2018
Cenkos: Creo Medical Group Plc - Momentum continues to build
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Creo Medical Group Plc - Momentum continues to build
Creo Medical Group Plc (CREO:LON) | 34.5 0 0.0% | Mkt Cap: 124.7m
- Published:
28 Sep 2018 -
Author:
Chris Donnellan -
Pages:
7
Creo Medical has announced its interim results to 30 June 2018. Undoubtedly this has been a strong period for the company with its lead product having been used clinically outside of the UK for the first time. Additionally, framework distribution agreements have been completed in the UK and South Africa and with Pentax in Asia-Pacific and 45 clinicians have been successfully trained as of 28 August 2018. Post-period end the company successfully raised £48.5m (gross) in an oversubscribed placing. ....